

Ref: FOI/GS/ID 5478

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

18 October 2019

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Cancer treatment.

You asked:

1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following

Paclitaxel

Gemcitabine

Osimertinib

Carboplatin and Pemetrexed

Cisplatin and Pemetrexed

Pembrolizumab monotherapy

Pembrolizumab in combination

Atezolizumab

Nivolumab

Other active systemic anti-cancer therapy

2a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Non Small Cell Lung cancer patients ?

2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:

Cetuximab not in combination with FOLFIRIE or FOLOX

Cetuximab in combination with FOLFIRI

Cetuximab in combination with FOLFOX

Panitumumab not in combination with FOLFIRI or FOLFOX

Panitumumab in combination with FOLFIRI

Panitumumab in combination with FOLFOX

Nivolumab

Aflibercept

Bevacizumab

Ramucirumab

Regorafenib

Sorafenib

Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)

3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?

3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?

4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?

Locally advanced

Recurrent metastatic

Unable to split

4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)

Carboplatin (only or in combination with 5-FU)

Cisplatin (only or in combination with 5-FU)

Cetuximab with / without chemotherapy

Cetuximab with radiotherapy

Pembrolizumab monotherapy

Pembrolizumab with chemotherapy

Nivolumab

Docetaxel (only or in combination with 5-FU)

Fluorouracil (5-FU)

Radiotherapy only

Other

4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?

4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:

Cisplatin single agent

Cisplatin in combination with another agent

Carboplatin single agent

Carboplatin in combination with another agent

Nivolumab

Pembrolizumab

Atezolizumab

Other active systemic anti-cancer therapy

5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?

5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

Trust response:

1. The Trust is unable to supply this information as we are in a process of cleaning to provide SNOMED code, some NSCLC patient may just have an indication of lung.

2a. Yes

2b. ARIAD 1 patient

3.

Cetuximab not in combination with FOLFIRIE or FOLOX Nil

Cetuximab in combination with FOLFIRI 23

Cetuximab in combination with FOLFOX Nil

Panitumumab not in combination with FOLFIRI or FOLFOX Nil

Panitumumab in combination with FOLFIRI 2

Panitumumab in combination with FOLFOX Nil

Nivolumab 1

Aflibercept Nil

Bevacizumab Nil

Ramucirumab Nil

Regorafenib Nil

Sorafenib Nil

Other active systemic anti-cancer therapy (e.g. 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU) 214

Figures for April-Sept 2019.

3a. Yes

3b. Add Aspirin, Ballard, Focus 4, Impress, Neoart, Polem, TRACC, NICEFIT, ONCORE. 21 in total at present on treatment.

4. None

4a. Not applicable

4b. None

4c. Not at present.

4d. Not applicable

5. None

5a. Not at present.

5b. Not applicable.